Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 10/20 | 0.50 |
| ▸ | CALCR | P30988 | 10/20 | 0.50 |
| ▸ | GLP1R | P43220 | 4/20 | 0.47 |
| ▸ | SCTR | P47872 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.47 |
| ▸ | NPY1R | P25929 | 2/20 | 0.47 |
| ▸ | NPY4R | P50391 | 2/20 | 0.47 |
| ▸ | APLNR | P35414 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30883242 | 0.89 | GLP1R (0.56) | RAMP3CALCRGLP1RSCTR | |
| SCHEMBL31307935 | 0.89 | GLP1R (0.50) | RAMP3CALCRGLP1RSCTR | |
| SCHEMBL29964770 | 0.88 | GLP1R (0.50) | RAMP3CALCRGLP1RSCTRAPLNR | |
| SCHEMBL29965306 | 0.88 | GLP1R (0.57) | RAMP3CALCRGLP1RSCTRNPY5R | |
| SCHEMBL29964887 | 0.87 | NPY4R (0.57) | GLP1RSCTRNPY5RNPY1RNPY4R | |
| SCHEMBL31467531 | 0.86 | C5AR1 (0.44) | GLP1RSCTRNPY5RNPY1RNPY4R | |
| SCHEMBL29962070 | 0.86 | GLP1R (0.52) | GLP1RSCTR | |
| SCHEMBL29659772 | 0.86 | NPY4R (0.47) | NPY5RNPY1RNPY4RAPLNR | |
| SCHEMBL30706289 | 0.86 | GLP1R (0.43) | RAMP3CALCRGLP1RSCTRAPLNR | |
| SCHEMBL31236840 | 0.86 | RAMP3 (0.48) | RAMP3CALCRGLP1RSCTRNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4438029-A | CONTROLLING SMOOTH MUSCLE CONTRACTION, HISTAMINE RELEASE, AND VASCULAR PERMEABILITY | RESEARCH CORPORATION (US) | 1984-03-20 | — | — | US | disclosed |